OrthoPediatrics (NASDAQ:KIDS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Friday.
Other equities research analysts also recently issued research reports about the company. Truist Financial decreased their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Needham & Company LLC restated a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday, May 8th. Piper Sandler decreased their price objective on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 price objective for the company. Finally, Stifel Nicolaus decreased their price objective on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, OrthoPediatrics currently has an average rating of "Moderate Buy" and an average price target of $35.83.
Get Our Latest Stock Analysis on KIDS
OrthoPediatrics Trading Up 0.5%
KIDS stock traded up $0.11 during mid-day trading on Friday, reaching $21.48. The company's stock had a trading volume of 73,750 shares, compared to its average volume of 198,231. The company has a market cap of $521.75 million, a price-to-earnings ratio of -12.27 and a beta of 1.08. The business's 50 day moving average price is $21.39 and its 200 day moving average price is $23.08. The company has a current ratio of 6.19, a quick ratio of 2.99 and a debt-to-equity ratio of 0.21. OrthoPediatrics has a 12 month low of $19.52 and a 12 month high of $35.99.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The business had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. OrthoPediatrics had a negative return on equity of 7.03% and a negative net margin of 19.15%. On average, equities research analysts predict that OrthoPediatrics will post -0.93 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of KIDS. Millennium Management LLC purchased a new position in shares of OrthoPediatrics during the fourth quarter valued at approximately $9,798,000. Point72 Asset Management L.P. purchased a new position in OrthoPediatrics in the fourth quarter worth $7,450,000. Wasatch Advisors LP boosted its position in OrthoPediatrics by 47.2% in the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock worth $16,141,000 after purchasing an additional 223,217 shares during the last quarter. Wellington Management Group LLP boosted its position in OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock worth $24,601,000 after purchasing an additional 178,078 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY boosted its position in OrthoPediatrics by 1,607.0% in the first quarter. Paradigm Capital Management Inc. NY now owns 170,700 shares of the company's stock worth $4,204,000 after purchasing an additional 160,700 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock.
About OrthoPediatrics
(
Get Free Report)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Stories
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
